Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region

Opinion statement from China, Japan, Taiwan, Korea, and Australia

Dingwei Ye, Masatoshi Eto, Jin Soo Chung, Go Kimura, Wen Cheng Chang, Yen Hwa Chang, See Tong Pang, Jae Lyun Lee, Yuanjie Niu, Howard Gurney, Hirotsugu Uemura

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Rates of renal cell carcinoma (RCC) morbidity and mortality vary widely by geography, with increasing incidence in most countries. Interestingly, RCC incidence is significantly lower in Asian countries relative to other regions, which is attributed to environmental and genetic influences. Additionally, it has been demonstrated that different ethnic groups differ in their RCC characteristics which might lead to varied responses to therapy. In this review, physicians drawn from countries across the Asia-Pacific region - China, Japan, Taiwan, Republic of Korea, and Australia - take all available data into consideration to develop the first opinion statement on treatment of advanced RCC in the region. We have sought to determine what factors influence treatment patterns and availability of therapeutic agents in our respective countries, discussed whether these factors are fully justified or should be modified, and considered what additional efforts should be undertaken to optimize treatment outcomes in RCC. Additionally, we have addressed the limitations on treatment of RCC in the region, capturing the restrictive situations of targeted therapy use in the Asia-Pacific region, mainly because of drug availability and treatment reimbursement. Often this illustrates the gap between Western and regional or even among local guidelines, the opinions of leading physicians regarding the treatment, and the realistic access to agents for most patients. Proposals made in this document are based on clinical experience and data from clinical trials of RCC therapies in which Asian patients have been included.

Original languageEnglish
Pages (from-to)225-233
Number of pages9
JournalClinical Genitourinary Cancer
Volume12
Issue number4
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Korea
Taiwan
Renal Cell Carcinoma
China
Japan
Therapeutics
Physicians
Republic of Korea
Geography
Incidence
Proxy
Cell- and Tissue-Based Therapy
Ethnic Groups
Clinical Trials
Guidelines
Morbidity
Mortality
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region : Opinion statement from China, Japan, Taiwan, Korea, and Australia. / Ye, Dingwei; Eto, Masatoshi; Chung, Jin Soo; Kimura, Go; Chang, Wen Cheng; Chang, Yen Hwa; Pang, See Tong; Lee, Jae Lyun; Niu, Yuanjie; Gurney, Howard; Uemura, Hirotsugu.

In: Clinical Genitourinary Cancer, Vol. 12, No. 4, 01.01.2014, p. 225-233.

Research output: Contribution to journalReview article

Ye, Dingwei ; Eto, Masatoshi ; Chung, Jin Soo ; Kimura, Go ; Chang, Wen Cheng ; Chang, Yen Hwa ; Pang, See Tong ; Lee, Jae Lyun ; Niu, Yuanjie ; Gurney, Howard ; Uemura, Hirotsugu. / Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region : Opinion statement from China, Japan, Taiwan, Korea, and Australia. In: Clinical Genitourinary Cancer. 2014 ; Vol. 12, No. 4. pp. 225-233.
@article{f3ff9218cb114319834841c4209fc87a,
title = "Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region: Opinion statement from China, Japan, Taiwan, Korea, and Australia",
abstract = "Rates of renal cell carcinoma (RCC) morbidity and mortality vary widely by geography, with increasing incidence in most countries. Interestingly, RCC incidence is significantly lower in Asian countries relative to other regions, which is attributed to environmental and genetic influences. Additionally, it has been demonstrated that different ethnic groups differ in their RCC characteristics which might lead to varied responses to therapy. In this review, physicians drawn from countries across the Asia-Pacific region - China, Japan, Taiwan, Republic of Korea, and Australia - take all available data into consideration to develop the first opinion statement on treatment of advanced RCC in the region. We have sought to determine what factors influence treatment patterns and availability of therapeutic agents in our respective countries, discussed whether these factors are fully justified or should be modified, and considered what additional efforts should be undertaken to optimize treatment outcomes in RCC. Additionally, we have addressed the limitations on treatment of RCC in the region, capturing the restrictive situations of targeted therapy use in the Asia-Pacific region, mainly because of drug availability and treatment reimbursement. Often this illustrates the gap between Western and regional or even among local guidelines, the opinions of leading physicians regarding the treatment, and the realistic access to agents for most patients. Proposals made in this document are based on clinical experience and data from clinical trials of RCC therapies in which Asian patients have been included.",
author = "Dingwei Ye and Masatoshi Eto and Chung, {Jin Soo} and Go Kimura and Chang, {Wen Cheng} and Chang, {Yen Hwa} and Pang, {See Tong} and Lee, {Jae Lyun} and Yuanjie Niu and Howard Gurney and Hirotsugu Uemura",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.clgc.2014.01.007",
language = "English",
volume = "12",
pages = "225--233",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region

T2 - Opinion statement from China, Japan, Taiwan, Korea, and Australia

AU - Ye, Dingwei

AU - Eto, Masatoshi

AU - Chung, Jin Soo

AU - Kimura, Go

AU - Chang, Wen Cheng

AU - Chang, Yen Hwa

AU - Pang, See Tong

AU - Lee, Jae Lyun

AU - Niu, Yuanjie

AU - Gurney, Howard

AU - Uemura, Hirotsugu

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Rates of renal cell carcinoma (RCC) morbidity and mortality vary widely by geography, with increasing incidence in most countries. Interestingly, RCC incidence is significantly lower in Asian countries relative to other regions, which is attributed to environmental and genetic influences. Additionally, it has been demonstrated that different ethnic groups differ in their RCC characteristics which might lead to varied responses to therapy. In this review, physicians drawn from countries across the Asia-Pacific region - China, Japan, Taiwan, Republic of Korea, and Australia - take all available data into consideration to develop the first opinion statement on treatment of advanced RCC in the region. We have sought to determine what factors influence treatment patterns and availability of therapeutic agents in our respective countries, discussed whether these factors are fully justified or should be modified, and considered what additional efforts should be undertaken to optimize treatment outcomes in RCC. Additionally, we have addressed the limitations on treatment of RCC in the region, capturing the restrictive situations of targeted therapy use in the Asia-Pacific region, mainly because of drug availability and treatment reimbursement. Often this illustrates the gap between Western and regional or even among local guidelines, the opinions of leading physicians regarding the treatment, and the realistic access to agents for most patients. Proposals made in this document are based on clinical experience and data from clinical trials of RCC therapies in which Asian patients have been included.

AB - Rates of renal cell carcinoma (RCC) morbidity and mortality vary widely by geography, with increasing incidence in most countries. Interestingly, RCC incidence is significantly lower in Asian countries relative to other regions, which is attributed to environmental and genetic influences. Additionally, it has been demonstrated that different ethnic groups differ in their RCC characteristics which might lead to varied responses to therapy. In this review, physicians drawn from countries across the Asia-Pacific region - China, Japan, Taiwan, Republic of Korea, and Australia - take all available data into consideration to develop the first opinion statement on treatment of advanced RCC in the region. We have sought to determine what factors influence treatment patterns and availability of therapeutic agents in our respective countries, discussed whether these factors are fully justified or should be modified, and considered what additional efforts should be undertaken to optimize treatment outcomes in RCC. Additionally, we have addressed the limitations on treatment of RCC in the region, capturing the restrictive situations of targeted therapy use in the Asia-Pacific region, mainly because of drug availability and treatment reimbursement. Often this illustrates the gap between Western and regional or even among local guidelines, the opinions of leading physicians regarding the treatment, and the realistic access to agents for most patients. Proposals made in this document are based on clinical experience and data from clinical trials of RCC therapies in which Asian patients have been included.

UR - http://www.scopus.com/inward/record.url?scp=84904766934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904766934&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2014.01.007

DO - 10.1016/j.clgc.2014.01.007

M3 - Review article

VL - 12

SP - 225

EP - 233

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 4

ER -